Our Mission

We are dedicated to establishing a drug discovery and early-stage development company that is based on innovation, scientific rigor and integrity. Our goal is to create novel products to meet critical patient needs, including: Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and Novel therapies to improve the treatment of human neurological conditions.

 

Our Vision and Values

For Patients

For Sciences

For Our Partners

APRINOIA believes living quality and dignity matters. We envision a world free of neurological disorders and that cutting-edge sciences and technologies are translated to the clinic to provide the best care for all the patients.

APRINOIA strives to bring cutting-edge sciences and technologies to life. We will continue to impel new standards in scientific research through our discoveries, innovations and technologies.

APRINOIA welcomes global and local partners to share our vision and values. We work with our partners with a great level of flexibility to create values and achieve our goals.

 

Our Teams

Ming-Kuei Jang

Founder and CEO

Paul Tempest

Senior Vice President of Drug Discovery

Chin-Yin Tai

Vice President of Neurobiology

Pei-Han Juan

Director of Finance

Masaomi Miyamoto

Executive Vice President of R&D and Operations (Tokyo)

PJ Chen

Senior Vice President of Clinical Development

Feng Yu

Vice President of Operations and Business Development (Suzhou)

Chien-Hui Hung

Director of Operations

Research & Development

/ Focus

Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.

Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.

Tao

Alzheimer’s Disease

 

Research & Development

Focus

APRINOIA discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.

Aprinoia discovers and develops first-in-class diagnostics and therapeutics for Alzheimer’s Disease (AD) and other tau-associated neurodegenerative diseases (Tauopathies). We achieve our mission by building comprehensive internal drug discovery and development capabilities and integrative collaborations with world-class scientists, research institutions and pharmaceutical companies to bring innovative ideas and scientific discoveries to life.

Tau

Tau mechanism

Alzheimer’s Disease

Alzheimer’s Disease

Tauopathies

Tauopathies are neurodegenerative disorders caused by aggregation of Tau proteins with formations of neurofibrillary tangles. 
Tau aggregates are not only found in AD, but also non-AD neurodegenerative diseases, including FTD, PSP, and CBS.

Synucleinopathies

Synucleinopathies are neurodegenerative disorders caused by abnormal aggregation of alpha-synuclein proteins with formations of insoluble fibrils.  

Alpha-synuclein aggregates are found in major families of synucleinopathies, which include  Parkinson Disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). 
 

Solutions

Diagnostics

APRINOIA is developing PET imaging tracers to detect the presence of NFT in the brain. Our technology will enable clinicians to monitor accurately the disease progression of Alzheimer’s and tauopathies and prompt early diagnosis and treatment of the diseases. In addition, our technology will enable the development of new therapeutics against the diseases by accurately assessing the efficacy of each development programme.

Therapeutics

APRINOIA has created a library of compounds that have shown therapeutic efficacy to Alzheimer’s and tauopathies.

Pipeline

APN_Pipeline_2020July.png
 
 
 

Our Partners

 

News

December 30, 2020

Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery

Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico’s novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative diseases.

December 16, 2020

APRINOIA Therapeutics Established Collaboration on Tau PET Imaging Tracer Development

APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, for neurodegenerative diseases. This is an extension of a collaboration between APRINOIA and Biogen to discover novel PET imaging tracers for visualization and quantification of abnormal tau protein accumulation in the brain.

October 28, 2020

APRINOIA Announces Approval from NMPA to Initiate Phase 3 Clinical Trial in China for 18F-APN-1607 Tau PET Imaging Tracer for Dementia

APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment.

November 21, 2019

Initiation of a Phase 2 Multicenter Study of 18F-APN-1607, a Novel Diagnostic PET Imaging Tracer for the Characterization of Tau Burden in Alzheimer’s Disease

APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of 18F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer's Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns in healthy older adults.

August 30, 2019

APRINOIA Therapeutics has Initiated a Collaboration with Keio University in Tokyo, Japan

APRINOIA Therapeutics has initiated a collaboration with Keio University in Tokyo, Japan to profile patients with dementia using APRINOIA’s tau PET imaging tracer, 18F-APN-1607 (PM-PBB3). The collaboration is a part of the EKID (Eisai-Keio Innovation Laboratory for Dementia) study conducted by Keio University and Eisai Co. Ltd., which is supported by a research grant (No. JP17pc0101006) from AMED (Japan Agency for Medical Research and Development). APRINOIA is grateful for the opportunity to contribute to the study which might be useful for deeper understanding of dementia, especially Alzheimer’s Disease.

July 01, 2019

APRINOIA Therapeutics Selected and Joined JLABS @ Shanghai

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that it has been selected to join Johnson & Johnson Innovation’s JLABS and is now a resident company of JLABS @ Shanghai.

 

For more information, please click on “More” for the original press release from Johnson & Johnson Innovation.

May 23, 2019

APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research

APRINOIA Therapeutics announces today that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.

March 26, 2019

2019 Taiwan Top 10 Coolest Tech Startups

APRINOIA was awarded as one of the top ten most innovative startups of Taiwan in 2019 by the Ministry of Science & Technology.

 
 

Careers

This information will be updated shortly.
 

Contact Us

Aprinoia Logo

台灣

Email        : contact@aprinoia.com 

地址          : 11503 臺北市南港區園區街3號17樓 

辦公室電話: +886-2-2655-8868

Taiwan
 
Address     : 17F, No.3, Park St., Nangang District, Taipei City 11503

Phone        : +886-2-2655-8868

-------------------------------------------------------------------------------------------------------​

中国大陆

邮箱          : contact@aprinoia.com 
地址       
  : 苏州市工业园区星湖街218号 生物医药产业园B2号楼5楼503室 215123

办公室电话: +86-512-8777 8382

China

Address    : R503,5F,Building B2,218 Xing Hu Rd,Suzhou Industrial Park,Suzhou 215213

Phone       : +86-512-8777 8382

-------------------------------------------------------------------------------------------------------​

日本

Email        : contact@aprinoia.com

所在地       : 〒104ー0033 東京都中央区新川1-2-8 第5山京ビル5F

Tel              +81-3-6280-4277

Japan

Address    : Shinkawa 1-2-8, Chuo-ku, Tokyo 104-0033, Japan

Phone         +81-3-6280-4277